1812 Ashland Avenue, 1st Floor
About WindMIL Therapeutics
When it comes to cell therapy – cell source matters. At WindMIL, we are harnessing the power of bone marrow derived lymphocytes (MILs) to develop ground-breaking immunotherapies to treat cancer patients. The bone marrow is a natural reservoir of T cells with unique advantages including inherent tumor-specificity. We have perfected an efficient and rapid process to extract, activate and expand MILs for future commercial applications. Our lead program is in a large Phase 2b study in high-risk multiple myeloma with additional programs in solid tumors using MILs advancing to the clinic. We are also advancing programs to supercharge MILs through genetic-modification.
Founders: Ivan Borrello, MD and Kimberly Noonan, PhD
CEO: Brian Halak, PhD
CMO: Dr. Steven Fischkoff
CSO: Kimberly Noonan, PhD
Please click here for WindMIL's technology.
12 articles with WindMIL Therapeutics
5/7/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
6/1/2020In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
4/27/2020Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
WindMIL Therapeutics and Cognate BioServices Announce Agreement to Expand MILs Manufacturing Capacity
WindMIL Therapeutics and Cognate BioServices, Inc. announced they have entered an agreement to expand WindMIL’s clinical manufacturing capacity.
WindMIL Therapeutics and Providence Cancer Institute Announce Collaboration to Collect Bone Marrow from Patients with Breast Cancer to Develop Marrow-Infiltrating Lymphocytes (MILs™)
WindMIL Therapeutics and Providence Cancer Institute announced that the first patient has been identified in an investigator-sponsored study for the collection of bone marrow from patients with breast cancer.
WindMIL Therapeutics Announces Cancer Immunotherapy Pre-Clinical Research Collaboration with University of Pennsylvania
WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today announced a collaborative pre-clinical research partnership with University of Pennsylvania (Penn) to explore novel chimeric antigen receptor (CAR)-engineered MILs (CAR-MILs™) in hematological and solid tumor model settings.
WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs™) in Combination with nivolumab (Opdivo®) for Treatment of Patients with Non-Small Cell Lung Cancer
This open-label, multi-center Phase 2a clinical trial will assess the safety and efficacy of MILs alone and in combination with nivolumab.
12/16/2019It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
WindMIL Therapeutics and University of Michigan Announce Collaboration to Collect Bone Marrow from Patients with Head and Neck Cancer to Develop Marrow Infiltrating Lymphocytes (MILs™)
WindMIL Therapeutics and the University of Michigan Rogel Cancer Center today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with head and neck squamous cell carcinoma.
Phase 2, multi-center randomized trial of MILs™ in high-risk multiple myeloma fully enrolled
WindMIL Therapeutics, based in Baltimore, Maryland, filed a form D with the U.S. Securities and Exchange Commission, indicating it had raised $32.53 million in equity financing.
WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based On Marrow-Infiltrating Lymphocytes